Interleukin-encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infection

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Ohs, Inga ^a   Windmann, Sonja ^a   Wildner, Oliver ^b   Dittmer, Ulf ^a   Bayer, Wibke ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GLYCOPROTEIN GP 70; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; FEMALE; FRIEND LEUKEMIA VIRUS; GENETIC IMMUNIZATION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PROTECTION; RETROVIRUS INFECTION; SPLENOMEGALY; TH2 CELL; VIRUS LOAD;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; FEMALE; FRIEND MURINE LEUKEMIA VIRUS; GENETIC VECTORS; HUMANS; INTERLEUKINS; MICE; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; SPLENOMEGALY; T-LYMPHOCYTE SUBSETS; VACCINATION; VIRAL VACCINES; VIRUS REPLICATION;

EID: 84891784029     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082528     Document Type: Article

References (49)

1. Fauci AS, Fischinger PJ (1988) The development of an AIDS vaccine: progress and promise. Public Health Rep 103: 230-236. PubMed: 3131812.
2. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671. doi:10.1086/508748. PubMed: 17109337.
3. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893. doi:10.1016/S0140-6736(08)61591-3. PubMed: 19012954.
4. National Institute of Allergy and Infectious Diseases (NIAID) (2013) NIH Discontinues Immunizations in HIV Vaccine Study. Available: http://www.hvtn.org/ 505-announcement-25April2013.html. Accessed 2013 November 6
5. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. doi:10.1056/NEJMoa0908492. PubMed: 19843557.
6. Dittmer U, Brooks DM, Hasenkrug KJ (1999) Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat Med 5: 189-193. doi:10.1038/5550. PubMed: 9930867.
7. Sun C, Zhang L, Zhang M, Liu Y, Zhong M et al. (2010) Induction of balance and breadth in the immune response is beneficial for the control of SIVmac239 replication in rhesus monkeys. J Infect 60:371-381. doi:10.1016/j.jinf.2010.03.005. PubMed: 20227437.
8. Gardner MB, Rosenthal A, Jennings M, Yee JA, Antipa L et al. (1994) Passive immunization of macaques against SIV infection. J Med Primatol 23: 164-174. doi:10.1111/j.1600-0684.1994.tb00118.x. PubMed: 7966232.
9. Gardner M, Rosenthal A, Jennings M, Yee J, Antipa L et al. (1995) Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res Hum Retroviruses 11: 843-854. doi:10.1089/aid.1995.11.843. PubMed: 7546912.
10. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R et al. (1999) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5: 204-210. doi:10.1038/5568. PubMed: 9930869.
11. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210. doi:10.1038/72318. PubMed: 10655111.
12. Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V (2010) Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics 5: 30-55. doi:10.1186/1479-7364-5-1-30. PubMed: 21106488.
13. Gilmour J, Lavender P (2008) Control of IL-4 expression in T helper 1 and 2 cells. Immunology 124: 437-444. doi:10.1111/j.1365-2567.2008.02845.x. PubMed: 18479352.
14. Kouro T, Takatsu K (2009) IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 21: 1303-1309. doi:10.1093/intimm/dxp102. PubMed: 19819937.
15. Eto D, Lao C, DiToro D, Barnett B, Escobar TC et al. (2011) IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh). Differentiation - PLOS ONE 6: e17739. doi:10.1371/journal.pone.0017739.
16. Murray R, Suda T, Wrighton N, Lee F, Zlotnik A (1989) IL-7 is a growth and maintenance factor for mature and immature thymocyte subsets. Int Immunol 1: 526-531. doi:10.1093/intimm/1.5.526. PubMed: 2518727.
17. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y et al. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725. doi:10.1016/S1074-7613(00)00070-4. PubMed: 11114383.
18. Friend C (1957) Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. J Exp Med 105: 307-318. doi: 10.1084/jem.105.4.307. PubMed: 13416470.
19. Bayer W, Lietz R, Ontikatze T, Johrden L, Tenbusch M et al. (2011) Improved vaccine protection against retrovirus infection after coadministration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology 8: 75. doi:10.1186/1742-4690-8-S1- A75. PubMed: 21943056.
20. Lietz R, Bayer W, Ontikatze T, Johrden L, Tenbusch M et al. (2012) Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection. J Virol 86: 1706-1716. doi:10.1128/JVI.06244-11. PubMed: 22090142.
21. Bayer W, Tenbusch M, Lietz R, Johrden L, Schimmer S et al. (2010) Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-Interleukin-cell responses and confers enhanced protection. J Virol 84: 1967-1976. doi:10.1128/JVI.01840-09. PubMed: 20007267.
22. Bayer W, Schimmer S, Hoffmann D, Dittmer U, Wildner O (2008) Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies. Vaccine 26: 716-726. doi:10.1016/j.vaccine.2007.11.050. PubMed: 18160188.
23. Messer RJ, Dittmer U, Peterson KE, Hasenkrug KJ (2004) Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A 101: 12260-12265. doi:10.1073/pnas. 0404769101. PubMed: 15297622.
24. Lynch RM, Yamamoto T, McDermott AB (2013) HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection. Curr Opin HIV AIDS 8: 288-294. PubMed: 23666390.
25. Boniface K, Blom B, Liu YJ, de Waal Malefyt R (2008) From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 226: 132-146. doi:10.1111/j.1600-065X.2008.00714.x. PubMed: 19161421.
26. Ha SJ, Kim DJ, Baek KH, Yun YD, Sung YC (2004) IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J Immunol 172: 525-531. PubMed: 14688363.
27. Williman J, Lockhart E, Slobbe L, Buchan G, Baird M (2006) The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. Vaccine 24: 4471-4474. doi:10.1016/j.vaccine. 2005.08.011. PubMed: 16140432.
28. Kishimoto T (2010) IL-6: from its discovery to clinical applications. Int Immunol 22: 347-352. doi:10.1093/intimm/dxq030. PubMed: 20410258.
29. Stahl-Hennig C, Gundlach BR, Dittmer U, ten Haaft P, Heeney J et al. (2003) Replication, immunogenicity, and protective properties of liveattenuated simian immunodeficiency viruses expressing interleukin-4 or interferon-gamma. Virology 305: 473-485. doi:10.1006/viro.2002.1763. PubMed: 12573592.
30. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M et al. (2001) Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 3: 697-707. doi:10.1006/mthe.2001. 0329. PubMed: 11356075.
31. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ et al. (2001) A potential role for interleukin-7 in T-cell homeostasis. Blood 97: 2983-2990. doi:10.1182/blood.V97.10.2983. PubMed: 11342421.
32. von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE et al. (1995) Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 181: 1519-1526. doi:10.1084/jem.181.4.1519. PubMed: 7699333.
33. Grabstein KH, Waldschmidt TJ, Finkelman FD, Hess BW, Alpert AR et al. (1993) Inhibition of murine B and T lymphopoiesis in vivo by an antiinterleukin 7 monoclonal antibody. J Exp Med 178: 257-264. doi:10.1084/jem.178.1.257. PubMed: 8315381.
34. Kittipatarin C, Khaled AR (2007) Interlinking interleukin-7. Cytokine 39: 75-83. doi:10.1016/j.cyto.2007.07.183. PubMed: 17768066.
35. Corfe SA, Paige CJ (2012) The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation. Semin Immunol 24: 198-208. doi:10.1016/j.smim.2012.02.001. PubMed: 22421572.
36. Gödel P, Windmann S, Dietze KK, Dittmer U, Bayer W (2012) Modification of one epitope-flanking amino acid allows for the induction of friend retrovirus-specific CD8+ T cells by Adenovirus-based immunization. J Virol 86: 12422-12425. doi:10.1128/JVI.01607-12. PubMed: 22933287.
37. Brenchley JM, Ruff LE, Casazza JP, Koup RA, Price DA et al. (2006) Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol 80: 6801-6809. doi:10.1128/JVI. 00070-06. PubMed: 16809286.
38. Masek-Hammerman K, Li H, Liu J, Abbink P, La Porte A et al. (2010) Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol 84: 9810-9816. doi:10.1128/JVI.01157-10. PubMed: 20686023.
39. Uberla K (2008) HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection? PLoS Pathog 4: e1000114. PubMed: 18769723.
40. Tenbusch M, Ignatius R, Temchura V, Nabi G, Tippler B et al. (2012) Risk of immunodeficiency virus infection may increase with vaccine-induced immune response. J Virol 86: 10533-10539. doi:10.1128/JVI.00796-12. PubMed: 22811518.
41. Lander MR, Chattopadhyay SK (1984) A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses. J Virol 52: 695-698. PubMed: 6092693.
42. Nilsson M, Ljungberg J, Richter J, Kiefer T, Magnusson M et al. (2004) Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 6: 631-641. doi:10.1002/jgm.543. PubMed: 15170734.
43. Ishihara C, Miyazawa M, Nishio J, Chesebro B (1991) Induction of protective immunity to Friend murine leukemia virus in genetic nonresponders to virus envelope protein. J Immunol 146: 3958-3963. PubMed: 2033265.
44. Mittereder N, March KL, Trapnell BC (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70: 7498-7509. PubMed: 8892868.
45. Chesebro B, Wehrly K, Stimpfling J (1974) Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med 140: 1457-1467. doi:10.1084/jem.140.6.1457. PubMed: 4430891.
46. Hasenkrug KJ, Brooks DM, Robertson MN, Srinivas RV, Chesebro B (1998) Immunoprotective determinants in friend murine leukemia virus envelope protein. Virology 248: 66-73. doi:10.1006/viro.1998.9264. PubMed: 9705256.
47. Sitbon M, Nishio J, Wehrly K, Lodmell D, Chesebro B (1985) Use of a focal immunofluorescence assay on live cells for quantitation of retroviruses: distinction of host range classes in virus mixtures and biological cloning of dual-tropic murine leukemia viruses. Virology 141: 110-118. doi:10.1016/0042- 6822(85)90187-4. PubMed: 2983493.
48. Robertson MN, Miyazawa M, Mori S, Caughey B, Evans LH et al. (1991) Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods 34: 255-271. doi:10.1016/0166-0934(91)90105-9. PubMed: 1744218.
49. Iwashiro M, Kondo T, Shimizu T, Yamagishi H, Takahashi K et al. (1993) Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol 67: 4533-4542. PubMed: 7687300.